drugset / Trial / NCT02627131

Autologous Bone Marrow Stem Cell Therapy for Autism

NCT02627131

Phase 2 Completed 24 enrolled Vinmec Healthcare System
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in the management of autism.

Timeline

Start
2014-04
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow mononuclear cells Cell therapy Intrathecal

Indications